Frontiers
US$ 22.61
mattson glp 1 CEO on food formulation in the Ozempic era Mattson probes Ozempic effect on
Description
The trial had been scheduled to begin in June in the U.S
Overweight and obesity are major global health issues, increasing disease risk and straining healthcare systems
Immunology drugs are still profitable
There is currently no strong evidence that GLP-1 receptor agonists directly cause thrombosis or blood clots
Phase two trials of the US biotech companys obesity pill showed weight loss of 12.2 percent but a higher rate of patient drop-off compared to a placebo.
